NEW YORK – An assay from Roche to test immunocompromised transplant recipients for adenovirus infections has been CE marked, the company announced on Wednesday. The test adds a fourth component to the firm's transplant monitoring virology menu and is now commercially available in countries accepting the CE mark.
The PCR-based adenovirus test provides detection and quantification of adenovirus, with calibration traceable to the World Health Organization international standard for adenovirus and reports in International Units per milliliter (IU/mL), the firm said in a statement.